Engineered immune cells take aim at Tough-to-Treat blood cancers
NCT ID NCT06879340
First seen May 17, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This early-phase trial tests a new treatment called DuoCAR-T for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and giving them back after a short chemotherapy course. The main goals are to find the safest dose and check for side effects in about 54 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Cancer Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.